Unlock stock picks and a broker-level newsfeed that powers Wall Street.
7.32
+0.18
+(2.52%)
At close: April 2 at 4:00:00 PM EDT
Key Executives
Amounts are as of December 31, 2024 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Michael Harvey Davidson FACC, Facp., M.D. | CEO, President, Executive Board Member & Director | 1.12M | -- | 1956 |
| Dr. Johannes Jacob Pieter Kastelein FESC, M.D., Ph.D. | Founder, Chief Scientific Officer, Member of Executive Board & Director | 813.08k | 4.09M | 1954 |
| Mr. Mayur Amrat Somaiya | Chief Financial Officer | 841.24k | -- | 1974 |
| Mr. Douglas F. Kling | Chief Operating Officer | 913.74k | -- | 1973 |
| Ms. Juliette Audet M.B.A., M.Sc. | Chief Business Officer | 653.04k | -- | 1987 |
| Ms. Louise Kooij | Chief Accounting Officer | -- | -- | 1976 |
| Mr. Matthew Philippe | Executive VP &Head of Investor Relations | -- | -- | -- |
| Mr. Bob Rambo | Executive Vice President of Marketing | -- | -- | -- |
| Ms. Maryellen McQuade | Chief People Officer | -- | -- | -- |
| Dr. Marc Ditmarsch M.D. | Chief Development Officer | -- | -- | 1967 |
NewAmsterdam Pharma Company N.V.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 68
Description
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.
Corporate Governance
NewAmsterdam Pharma Company N.V.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Upcoming Events
Upcoming Events Information Not Available
Recent Events
Recent Events Information Not Available
Related Tickers
688428.SS InnoCare Pharma Limited
18.48
-2.69%
6HN.DU Everest Medicines Ltd
6.65
+1.53%
4563.T AnGes, Inc.
64.00
+1.59%
ENTBF Entheon Biomedical Corp.
0.0890
0.00%
IVBIY Innovent Biologics Inc.
22.29
0.00%
IVBXF Innovent Biologics, Inc.
6.15
0.00%
6990.HK Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
309.000
-0.77%
CNBX CNBX Pharmaceuticals Inc.
0.0100
+23.46%
1952.HK Everest Medicines Limited
58.450
+2.90%
IPH.PA Innate Pharma S.A.
1.8260
-1.30%